Diffuse Intrinsic Pontine Glioma: Research
(asked on 7th November 2023) - View Source
Question to the Department of Health and Social Care:
To ask His Majesty's Government how much funding they have allocated for research into the treatment of Diffuse Intrinsic Pontine Glioma brain tumours in children in each of the last 10 years; and to which organisations were those funds allocated.
The following table shows eight research studies around Diffuse Intrinsic Pontine Glioma, funded by research funding partners in the charity and public sectors since 2013 which have been supported by the National Institute for Health and Care Research (NIHR):
Study Title | Opening Date | Closure Date | Funders | Status |
Phase I trial of afatinib in paediatric patients with neuroectodermal tumours and rhabdomyosarcoma | 13/07/2015 | 05/05/2020 | Boehringer Ingelheim Ltd | Closed to Recruitment, Follow Up Complete |
A Phase I/II, Multicenter, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients with Previously Treated Solid Tumors | 25/08/2016 | 31/12/2018 | F. Hoffmann-La Roche Ltd | Closed to Recruitment, In Follow Up |
Biological Medicine for Diffuse Intrinsic Pontine Glioma Eradication (Biomede) | 14/04/2017 | 29/09/2019 | Cancer Research UK | Closed to Recruitment, In Follow Up |
Phase Ib /II Clinical Trial of Nivolumab Monotherapy and Nivolumab in Combination with Ipilimumab in Pediatric Subjects with High Grade Primary CNS Malignancies | 14/08/2017 | 22/02/2019 | Bristol-Myers Squibb International Corporation | Closed to Recruitment, In Follow Up |
A PHASE 2 CLINICAL STUDY OF POMALIDOMIDE (CC-4047) MONOTHERAPY FOR CHILDREN AND YOUNG ADULTS WITH RECURRENT OR PROGRESSIVE PRIMARY BRAIN TUMORS | 17/10/2017 | 27/09/2018 | CELGENE CORPORATION | Closed to Recruitment, In Follow Up |
A Phase 1/2, Single-arm Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of Avapritinib in Pediatric Patients with Solid Tumors Dependent on KIT or PDGFRA Signaling | 15/02/2023 | 31/01/2025 | Blueprint Medicines Corporation | Suspended |
*** |
|
|
|
|
*** |
|
|
|
|
*** Please note that the 2 commercial studies, due to the commercial sensitivity, cannot be shared more widely or made public.
NIHR provides infrastructure support to studies taking place in the National Health Service. For example, staff, research nurses, local networks and NHS trusts will work across many studies, to varying degrees. As a result, NIHR cannot provide precise information on expenditure.
The NIHR Clinical Research Network supports the delivery of high-quality research across the NHS, community and social care and public health organisations. It does this by meeting the costs of additional staff, facilities, equipment and support services.
In May 2018 the Government announced £40 million for brain tumour research as part of the Tessa Jowell Brain Cancer Mission. The Government is committed to funding high-quality brain cancer research. The £40 million funding remains available.